Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

SER-262

Microbiome therapy · developed by Seres Therapeutics

Phase 1 Most advanced trial (none active)

MCRB Developer

1 Registered trials

What is SER-262?

SER-262 is a rationally designed microbiome therapeutic consisting of a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration. It is produced synthetically by in vitro fermentation and is studied in Clostridium difficile infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Microbiome therapy
Therapy area: Infectious disease
Developer: Seres Therapeutics, Inc. (MCRB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02830542	Phase 1	Clostridium Difficile Infection	Completed	MCRB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Clostridium Difficile Infection

More from Seres Therapeutics

SER-155 Phase 1 SER-287 Phase 2

Sources

ClinicalTrials.gov NCT02830542

Updated Oct 3, 2026. Something wrong or missing? Report it on the MCRB page.

Follow MCRB, the company behind SER-262

See MCRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MCRB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z